However, according to the analysis carried out by Salas et al. (2021) [15] in Spain in 2018, despite the relatively high testing rate reported in EGFR and ALK in NSCLC (91.4 and 80.1%, respectively), the real-world evidence obtained from the LungPath registry demonstrates that ROS1 and PD-L1 were not determined in a significant portion of patients (56.2 and 58.1%, respectively) [15]. This evidence concerns the gene ALK and non-small cell lung carcinoma.